OCULAR THERAPEUTIX, INC (OCUL) — SEC Financial Statements & Analysis

OCULAR THERAPEUTIX, INC (OCUL) is a pharmaceutical preparations company, incorporated in DE. OCULAR THERAPEUTIX, INC trades on Nasdaq as: OCUL. OCULAR THERAPEUTIX, INC (OCUL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, OCULAR THERAPEUTIX, INC carries a market cap of $2.21B, a P/E ratio of -7.33x, a P/B ratio of 4.25x, a P/S ratio of 42.44x, an enterprise value of $1.68B, and an EV/EBITDA multiple of -5.45x. On profitability, it posts a gross margin of 87.11%, an operating margin of -603.04%, a net margin of -579.10%, a Return on Equity (ROE) of -72.99%, and a Return on Assets (ROA) of -53.70%. Per share, it reports EPS of $-1.34, diluted EPS of $-1.34, free cash flow per share of $-1.13, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -8.14% year-over-year, net income growth of 39.08% year-over-year, and EPS growth of 6.71% year-over-year. On the balance sheet, it maintains a current ratio of 13.11x, a quick ratio of 12.79x, working capital of $595.25M, a debt-to-equity ratio of 0.29x, a debt ratio of 0.23, an interest coverage ratio of -27.53x, free cash flow of $-255.10M (TTM), and net debt of $-527.46M. Figures sourced from SEC EDGAR.

Market Cap

$2.21B

P/E TTM

-7.33x

EPS TTM

$-1.34

P/B TTM

4.25x

ROE TTM

-72.99%

ROA TTM

-53.70%

Debt To Equity

0.29x

Free Cash Flow TTM

$-255.10M

Net Revenue TTM Growth 1Y

-8.14%

Data as of 2026-06-30 · Source: SEC EDGAR